| Basal cell carcinoma
Libtayo vs Odomzo
Side-by-side clinical, coverage, and cost comparison for basal cell carcinoma.Deep comparison between: Libtayo vs Odomzo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdomzo has a higher rate of injection site reactions vs Libtayo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odomzo but not Libtayo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Libtayo
Odomzo
At A Glance
IV infusion
Every 3 weeks
PD-1 inhibitor
Oral
Daily
Hh pathway inhibitor
Indications
- Squamous cell carcinoma of skin
- Basal cell carcinoma
- Non-Small Cell Lung Carcinoma
- Basal cell carcinoma
Dosing
Squamous cell carcinoma of skin (metastatic/locally advanced) 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Squamous cell carcinoma of skin (adjuvant) 350 mg IV infusion every 3 weeks for 12 weeks followed by 700 mg every 6 weeks, or 350 mg every 3 weeks, until disease recurrence, unacceptable toxicity, or up to 48 weeks.
Basal cell carcinoma 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Non-Small Cell Lung Carcinoma 350 mg IV infusion every 3 weeks as single agent or in combination with platinum-based chemotherapy until disease progression or unacceptable toxicity.
Basal cell carcinoma 200 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Fatigue, musculoskeletal pain, rash, diarrhea, anemia.
Serious Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, exfoliative dermatologic conditions, myocarditis, neurological toxicities), infusion-related reactions, allogeneic HSCT complications, pneumonia.
Most common (>=10%) Muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, pruritus
Serious Musculoskeletal adverse reactions
Pharmacology
Cemiplimab-rwlc is a recombinant human IgG4 monoclonal antibody (PD-1 inhibitor) that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Sonidegib is an Hh pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Libtayo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Odomzo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Libtayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Odomzo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Libtayo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Odomzo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$10/momo
Odomzo Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LibtayoView full Libtayo profile
OdomzoView full Odomzo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.